New Report Highlights Need for Long Term View to Improve Cancer Care (y 2)

        
        - In recent years, significant changes in the regulative procedures for
          reimbursement and pricing of pharmaceuticals have occurred in all countries included
          within the report but Sweden. In France and especially in Germany, the main reason for
          these changes was cost containment of pharmaceutical expenditures.[1]
        - Germany was the last of the four countries to introduce a mandatory assessment
          of all new pharmaceuticals claiming public funding in 2011. It is also the only
          country where the therapeutic relevance of pharmaceuticals (additional benefit claimed
          over the appropriate comparator when a new product is launched or authorised for new
          indications) is the main criterion used to inform the reimbursement decision.[1],[5]
        - The "high" cost of cancer drugs has already led to substantial changes in the
          reimbursement policy in Germany in 2011 and in France in 2013. However, the share of
          the pharmaceutical expenditures on total health expenditures did not increase in any
          of the four countries between 2003 and 2011.[1]

Cancer costs

        
        - Cancer corresponds to around 16% of the total health burden of all disease
          and illnesses in the EU.[1]
        - The share of cancer-related direct costs on total health care expenditures
          ranges from 5% in Poland to 7.3% in Sweden; however, purchasing power adjusted
          per-capita spending on cancer is around four times higher in Sweden, Germany and
          France than in Poland.[1]
        - The share of cancer-related indirect costs on total costs is around 60% in the
          EU but differs greatly between cancer types.[6]
        - Lung cancer accounts for around 15% of the total direct and indirect cost of
          cancer in the EU, colorectal cancer for 10% and prostate cancer for 7%.[6]
        - Cancer also accounts for more than 10 million DALYs (disability-adjusted life
          years) lost in the European Union. This corresponds to a share of around 16% of the
          total health burden of all diseases and illnesses.[7]
        - The cancer disease burden does not exhibit a uniform pattern across all cancer
          types.[1]

About the report

The "Access to high-quality oncology care across Europe" report [http://www.ihe.se/access-to-high-quality-oncology.aspx ] was commissioned by Janssen Pharmaceutica NV and based on independent research delivered by The Swedish Institute of Health Economics (IHE). Janssen has no editorial control over the content of the document, and the views and opinions of the authors are not necessarily those of Janssen.

Additional information about the report can be found on the Janssen Health Policy Center http://www.janssen-emea.com/healthpolicycenter.

About Janssen

Janssen Pharmaceutical Companies of Johnson and Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on http://www.janssen-emea.com. Follow us on http://www.twitter.com/janssenEMEA for our latest news.

Janssen in Oncology

In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include a focus on haematologic malignancies, prostate cancer and lung cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.

About The Swedish Institute of Health Economics

IHE is a well-established and independent research institute specialised in health economic analysis. It provides high quality research and expert consulting within the health care field. IHE contributes to well-founded decision-making in healthcare by bridging the gap between academia, industry and health care providers. IHE is based in Lund, Sweden, and is part of the dynamic Medicon Village area. IHE has been a pioneer in health economic research in Sweden since 1979 and has a strong academic profile with close ties to Lund University.

References

        
        1) Hofmarcher T, Jönsson B, Wilking N. Access to high-quality oncology care
          across Europe. Lund: Swedish Institute for Health Economics, 2014. Available at:
          http://www.ihe.se/access-to-high-quality-oncology.aspx (accessed Apr 3, 2014).
        2) Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW,
          Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe:
          estimates for 40 countries in 2012. Eur J Cancer.2013;49:1374-403.
        3) Eurostat. EU28 population 505.7 million at 1 January 2013. Press release 20
          November 2013. Available at:
          http://epp.eurostat.ec.europa.eu/cache/ITY_PUBLIC/3-20112013...
          (accessed Mar 31, 2014).
        4) Krankenkassen. 2013. Available at:
          http://www.krankenkassen.de/gesetzliche-krankenkassen/system...
          erung/fusionen/
          [http://www.krankenkassen.de/gesetzliche-krankenkassen/system... ]
          (accessed March 21, 2014).
        5) Gemeinsamer Bundesausschuss (G-BA). The benefit assessment of pharmaceuticals
          in accordance with the German Social Code, Book Five (SGB V), section 35a. Available
          at: http://www.english.g-ba.de/benefitassessment/information/
          [http://www.english.g-ba.de/benefitassessment/information ] (accessed March 21,
          2014).
        6) Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of
          cancer across the European Union: a population-based cost analysis. Lancet
          Oncol.2013;14:1165-74.
        7) World Health Organization. Mortality and burden of disease estimates for WHO
          member states in 2004: DALY 2004. Available at:
          http://www.who.int/healthinfo/global_bur...
          (accessed March 12, 2014).

CONTACT: EU Media Inquiries: Satu Kaarina Glawe, Phone:+49(0)2638-947-9218, Mobile: +49(172)294-6264, Email: sglawe@its.jnj.com